Company intelligence / Profile preview

Primocyn Eau Divine

Manhattan Beach, California, United States

Ownership: Private
Development stage: Other

Overview

Primocyn Eau Divine’s hypochlorous acid (HOCl) skin solution is FDA-cleared (510(k)), non-toxic, kills 99.99% of bacteria and viruses in under 30 seconds, and is supported by 53 patents, with 17 FDA and 13 CE clearances; used for skin wounds, burns, ulcers, and eye care with no reported long-term side effects.

Therapeutic areas: OphthalmologyDermatology
Modalities: DeviceHydrogel-based drug delivery therapy (hydrogel formulation)Topical solution with hypochlorous acid
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Primocyn Eau Divine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primocyn Eau Divine.

Explore the full profile